glycine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 7 studies
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acute lymphoblastic leukemia (ALL) is a disease of lymphoid progenitor cells with an often aggressive course and is commonly caused by the BCR-ABL fusion gene t(9;22) in adults." | 1.72 | Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia. ( Appelmann, I; Brümmendorf, TH; Koschmieder, S; Maletzke, S; Masouleh, BK; Salimi, A; Schemionek, M; Schroeder, KM; Vieri, M, 2022) |
| "Acute and chronic myeloid leukemia are initiated and sustained by a small, self-renewing population of leukemic stem cells, which produce progeny of a heterogeneous population of progenitor cells." | 1.40 | Stromal cell derived factor-1 (CXCL12) chemokine gene variant in myeloid leukemias. ( Bahaa, NM; El-Ghany, HM; El-Saadany, ZA; Hussien, SM; Ibrahim, NY, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, C | 1 |
| Zou, W | 1 |
| Nie, D | 1 |
| Li, S | 1 |
| Duan, C | 1 |
| Zhou, M | 1 |
| Lai, P | 1 |
| Yang, S | 1 |
| Ji, S | 1 |
| Li, Y | 1 |
| Mei, M | 1 |
| Bao, S | 1 |
| Jin, Y | 1 |
| Pan, J | 1 |
| Maletzke, S | 1 |
| Salimi, A | 1 |
| Vieri, M | 1 |
| Schroeder, KM | 1 |
| Schemionek, M | 1 |
| Masouleh, BK | 1 |
| Brümmendorf, TH | 1 |
| Koschmieder, S | 1 |
| Appelmann, I | 1 |
| Navada, SC | 1 |
| Garcia-Manero, G | 1 |
| OdchimarReissig, R | 1 |
| Pemmaraju, N | 1 |
| Alvarado, Y | 1 |
| Ohanian, MN | 1 |
| John, RB | 1 |
| Demakos, EP | 1 |
| Zbyszewski, PS | 1 |
| Maniar, M | 1 |
| Woodman, RC | 1 |
| Fruchtman, SM | 1 |
| Silverman, LR | 1 |
| El-Ghany, HM | 1 |
| El-Saadany, ZA | 1 |
| Bahaa, NM | 1 |
| Ibrahim, NY | 1 |
| Hussien, SM | 1 |
| Okabe, S | 1 |
| Tauchi, T | 1 |
| Tanaka, Y | 1 |
| Sakuta, J | 1 |
| Ohyashiki, K | 1 |
| Engür, S | 1 |
| Dikmen, M | 1 |
| Öztürk, Y | 1 |
| FUJII, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia[NCT01926587] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for glycine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Glycine; Humans; Leukemia, Myelogenous, Chronic | 2020 |
6 other studies available for glycine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML.
Topics: Animals; Epigenesis, Genetic; Glycine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, M | 2022 |
Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Boron Compounds; Bortezomib; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr | 2022 |
Stromal cell derived factor-1 (CXCL12) chemokine gene variant in myeloid leukemias.
Topics: 3' Untranslated Regions; Adolescent; Adult; Aged; Alanine; Case-Control Studies; Chemokine CXCL12; F | 2014 |
Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Glycine; Humans; Leukemia, Myelogenous, Chronic, BC | 2015 |
Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells.
Topics: Apoptosis; Boron Compounds; Bortezomib; Cell Proliferation; Dose-Response Relationship, Drug; Drug S | 2016 |
BIOSYNTHESIS OF HEME AND STERCOBILIN IN CHRONIC MYELOID LEUKEMIA AND IRON DEFICIENCY ANEMIA. STUDY WITH 2-14C-GLYCINE.
Topics: Anemia; Anemia, Hypochromic; Anemia, Iron-Deficiency; Bile Pigments; Glycine; Heme; Humans; Leukemia | 1964 |